ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 May 2019
Last Updated on 04 Jan 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients:
    • with chronic heart failure classified by New York Heart Association (NYHA) Class II - IV symptoms; and
    • with left ventricular ejection fraction of 40% or less; and
    • who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and
    • who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.

Sacubitril/valsartan must not be co-administered with an ACE inhibitor or an ARB.

Subsidy status

Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.


Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction (4 Jan 2022) PES Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction (Published 4 Jan 2022)